Ann: Q4 FY22 Quarterly Activities Report & Appendix 4C, page-4

First 4 Last

Share
Profile

Follow
turbo

650 Posts.

481

21/07/22

11:29

Post #: 62648906
Share

Originally posted by triage: ↑

Agree, impressive. I do have one concern and a couple of queries.

At first blush I worry that Luke Reid is being a tad cocky with this comment: "In FY23 we will advance into the clinic with our lead IBD asset MAP315 which we expect to generate significant value for shareholders".

I seem to recall seeing claims that only about 6% of products that make it through phase 1 clinical trial go onto being commercialised (and from memory about 40% of phase 2 and 80% of phase 3 end up making it to market). MAP315 is not even at the start line for a phase 1 trial. Unless LR knows something that he is not telling us I think "hope" rather than "expect" would have been closer to reality.

A couple of questions: I wonder how much of that revenue figure for Q4FY22 was from sale of testing services and how much was from sales to research clients. It seems to me that the the testing services are scalable but the research clients not so much.

Also given that the new distributorship arrangements were only bedded down at the end of the June quarter I wonder how much of a revenue boost is expected in coming quarters from the new distributors and the new product. I can find no guidance at all in either the quarterly or the presentation deck let alone the sort of estimates that Lefevre kindly shared a while back.

And finally, an observation: for every set of test data they get approval to keep and use not only do they get more revenue dollars they also get more grist for their AI. I follow a few companies that claim to be trying to use big data to disrupt normal order. Most likely some are pretenders and some will be failures. But Microba seems as well placed as any with its microbiome analysis skills and its growing dataset of both health and bugs.

Expand

What he means by "advance into the clinic" is begin human clinical trials, not commercialise which would still be several years away and uncertain as you point out.

And I agree, some breakdown of revenues and, in particular, guidance would have been helpful.

MAP Price at posting: 29.0¢ Sentiment: Hold Disclosure: Not Held
2 Upvote

0 Great analysis

Reply

Top Stories

KAU

Kaiser Reef sets up $8M capital raising to boost expansion at A1 gold mine

HMX

Hammer to unlock North Orelia gold play with average recoveries of 94%

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Superannuation Essentials: Building Wealth for Your Retirement

WTC

A sex scandal is unlikely to hurt Australia's tech crown jewel – just look at trades

There are more pages in this discussion • 3 more messages in this thread...

First 4 Last

Add MAP (ASX) to my watchlist

(20min delay)
Last 17.0¢		Change 0.010(6.25%)		Mkt cap ! $76.13M

Open	High	Low	Value	Volume
17.0¢	17.0¢	17.0¢	$1.007K	5.923K

Buyers (Bids)

No.	Vol.	Price($)
1	1000	16.5¢

Sellers (Offers)

Price($)	Vol.	No.
17.0¢	67282	3

View Market Depth

No.	Vol.	Price($)
1	1000	0.165
5	131891	0.160
3	59451	0.155
4	183153	0.150
1	5000	0.145

Price($)	Vol.	No.
0.170	67282	3
0.175	139097	3
0.180	225121	6
0.190	236752	1
0.195	183206	1

Last trade - 13.46pm 21/10/2024 (20 minute delay)

MAP (ASX) Chart

Ann: Q4 FY22 Quarterly Activities Report & Appendix 4C, page-4

Kaiser Reef sets up $8M capital raising to boost expansion at A1 gold mine

Hammer to unlock North Orelia gold play with average recoveries of 94%

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Superannuation Essentials: Building Wealth for Your Retirement

A sex scandal is unlikely to hurt Australia's tech crown jewel – just look at trades

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Q4 FY22 Quarterly Activities Report & Appendix 4C, page-4

Top Stories

Kaiser Reef sets up $8M capital raising to boost expansion at A1 gold mine

Hammer to unlock North Orelia gold play with average recoveries of 94%

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Superannuation Essentials: Building Wealth for Your Retirement

A sex scandal is unlikely to hurt Australia's tech crown jewel – just look at trades

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News